Multiple Indications | Special Topics | Cancer Vaccines and Viral Therapies | G7 | 2016
The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies, making these therapies exciting to watch. Cancer Vaccines and Viral Therapies provides comprehensive multi-indication coverage of currently available cancer vaccines (Provenge in the United States and Imlygic in the United States and EU5) and analysis of their ongoing clinical development across the oncology indications. In addition, analysis of late-phase emerging therapies and their future positioning in oncology is provided based on insights from interviewed thought leaders and analysis of secondary market research sources. This analysis uniquely enables a comparison of the potential of the therapies in this drug class across a breath of indications in addition to determining their total peak-year sales across oncology indications.
